Navigation Links
MedImmune's Motavizumab Reduced RSV Hospitalizations by 83 Percent Among High-Risk Native American, Full-Term Infants in Placebo-Controlled Phase 3 study
Date:8/23/2007

in infants in the United States. RSV is the most common respiratory infection in infancy or childhood. Approximately one-half of all infants are infected with RSV during the first year of life, and nearly all children have been infected at least once by the time they reach their second birthday. Children born prematurely as well as those with chronic lung disease (CLD) or congenital heart disease (CHD) are at highest risk for severe disease and hospitalization due to RSV. The virus may also cause severe illness in other high-risk groups such as the elderly, those with underlying respiratory or cardiac disease, and those with compromised immune systems (e.g., bone marrow transplant patients).

About Motavizumab

Motavizumab, formerly known as Numax(R), is an investigational humanized MAb being evaluated for its potential to prevent serious lower respiratory tract disease caused by RSV in pediatric patients at high risk of RSV disease. Phase 1 and Phase 2 study data have been reported showing that motavizumab appears to have a similar safety and pharmacokinetic profile to Synagis in infants. Additionally, in early phase studies children treated with motavizumab had reduced RSV replication in the upper respiratory tract. In its first pivotal trial, which was a head-to-head comparative trial with Synagis, motavizumab demonstrated a 26-percent reduction in RSV hospitalizations due to RSV and a 50-percent reduction in the incidence of RSV lower respiratory tract infections requiring outpatient management, its secondary endpoint.

About Synagis

Synagis is the only monoclonal antibody approved by the FDA to help prevent an infectious disease. Synagis was approved for use in the United States in 1998, Europe in 1999, and Japan in 2002. Synagis is currently available in 62 countries.

Synagis is indicated for the prevention of serious lower respiratory tract disease caused by respiratory syncytial virus (RSV) in pediatric patients at high risk of RS
'/>"/>

SOURCE MedImmune, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
2. Publication on Pixantrone Preclinical Studies Demonstrates Reduced Cardiotoxicity Compared to Equiactive Doses of Doxorubicin and Mitoxantrone
3. New Study Shows A1c Reduced Safely By Patients With Type 2 Diabetes Using Self-Adjusted Dosing Starting With Once-Daily Insulin Treatment Levemir
4. Lipitor Reduced the Risk of Coronary Events by Half and Stroke by Nearly One-Third in High-Risk Patients with Type 2 Diabetes Who Experienced a Recent Stroke
5. New Study Shows A1c Reduced Safely By Patients With Type 2 Diabetes Using Self-Adjusted Dosing Starting With Once-Daily Insulin Treatment Levemir
6. Arterial Plaque Significantly Reduced in Women Age 50-59 Taking Hormones, Says New Analysis of Womens Health Initiative Data
7. New Analysis of WHI Data Shows Reduced Levels of Coronary Artery Calcification, a Predictor of Cardiovascular Events, in Women aged 50-59 taking Estrogen Therapy
8. Pivotal Phase III Trial Showed Promacta (eltrombopag olamine) Raised Platelet Counts and Reduced Bleeding in Patients With Chronic ITP
9. Preclinical Study Finds Protease Inhibitor-Resistant HIV May Have Reduced Potential to Develop Resistance to Panacos Bevirimat
10. New Analysis of Data Shows Treatment With Abbotts Humira (Adalimumab) Significantly Reduced Disease-Related Hospitalization for Patients with Crohns Disease
11. Data Suggest Cymbalta Reduced Severity of Night Pain in Patients with Diabetic Nerve Pain
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/16/2014)... Sept. 16, 2014  DNAtrix, Inc., experts in ... patient was treated with the company,s lead product, ... in a randomized, multicenter, open-label Phase Ib study ... in collaboration with leading neurosurgeons and neuro-oncologists in ... of our randomized Phase Ib study of DNX-2401 ...
(Date:9/16/2014)... 2014  Eli Lilly and Company (NYSE: ... agreement to co-develop and commercialize AZD3293, an oral ... development as a potential treatment for Alzheimer,s disease. ... characterized by the accumulation of amyloid plaque in ... the development of beta-amyloid. Inhibiting BACE is expected ...
(Date:9/15/2014)... WHIPPANY, N.J. , Sept. 16, 2014 /PRNewswire/ ... based in Espoo, Finland , ... III trial with ODM-201, an investigational oral androgen ... ARAMIS, evaluates ODM-201 in men with castration-resistant prostate ... levels and no detectable metastases. The trial is ...
Breaking Medicine Technology:DNAtrix Announces Treatment Of First Patient With DNX-2401 In Recurrent Glioblastoma Trial 2Lilly and AstraZeneca announce alliance to co-develop potential treatment for Alzheimer's disease 2Lilly and AstraZeneca announce alliance to co-develop potential treatment for Alzheimer's disease 3Lilly and AstraZeneca announce alliance to co-develop potential treatment for Alzheimer's disease 4Bayer and Orion Initiate Phase III Trial of ODM-201 in Men with High-Risk Non-Metastatic Castration-Resistant Prostate Cancer 2Bayer and Orion Initiate Phase III Trial of ODM-201 in Men with High-Risk Non-Metastatic Castration-Resistant Prostate Cancer 3
... and KOS, Greece, June 29, 2007 /PRNewswire/ --,The ... treated patients on REVLIMID (lenalidomide) plus the,steroid dexamethasone ... The data are pooled from two large randomized,controlled ... patients,from nearly 100 clinical sites worldwide. These updated ...
... at the 11th International Myeloma Workshop ... of perifosine in,combination with bortezomib, dexamethasone ... relapsed/refractory multiple,myeloma, and as a single ... NEW YORK, June 29, 2007 /PRNewswire-FirstCall/ ...
Cached Medicine Technology:The European Myeloma Platform Reports New Survival data for,Revlimid Presented at the International Myeloma Workshop in Greece 2Keryx Biopharmaceuticals, Inc. Announces Positive Phase I and Phase,II Data on KRX-0401 in Patients with Relapsed/Refractory Multiple,Myeloma and Waldenstrom's Macroglobulinemia 2Keryx Biopharmaceuticals, Inc. Announces Positive Phase I and Phase,II Data on KRX-0401 in Patients with Relapsed/Refractory Multiple,Myeloma and Waldenstrom's Macroglobulinemia 3Keryx Biopharmaceuticals, Inc. Announces Positive Phase I and Phase,II Data on KRX-0401 in Patients with Relapsed/Refractory Multiple,Myeloma and Waldenstrom's Macroglobulinemia 4Keryx Biopharmaceuticals, Inc. Announces Positive Phase I and Phase,II Data on KRX-0401 in Patients with Relapsed/Refractory Multiple,Myeloma and Waldenstrom's Macroglobulinemia 5Keryx Biopharmaceuticals, Inc. Announces Positive Phase I and Phase,II Data on KRX-0401 in Patients with Relapsed/Refractory Multiple,Myeloma and Waldenstrom's Macroglobulinemia 6Keryx Biopharmaceuticals, Inc. Announces Positive Phase I and Phase,II Data on KRX-0401 in Patients with Relapsed/Refractory Multiple,Myeloma and Waldenstrom's Macroglobulinemia 7
(Date:9/16/2014)... adage that warns against passing judgment based on ... species, apparently don,t share such human wisdom when ... University Polytechnic School of Engineering found that female ... fin color: yellow. The preference for yellow was ... , The reason may lie in the engineering-based, ...
(Date:9/16/2014)... According to a new market ... Home Healthcare Market (By Device Types: Diagnostics and ... Devices and Medical Supplies; By Services: Rehabilitation, Telehealth ... Home Healthcare Services) - Industry Analysis, Size, Share, ... Latin American Home Healthcare market was valued at ...
(Date:9/16/2014)... Angeles, CA (PRWEB) September 16, 2014 ... Jack, are embarking on a 14-month journey around the ... international documentary web series project, titled ‘Million Ways to ... in order to highlight the healthy lifestyles of amazing, ... ‘Million Ways to Live’, the documentary series will focus ...
(Date:9/16/2014)... September 16, 2014 Today, Top 10 ... the most recommended suppliers for the webmasters for people ... save money at the same time. , As an ... ) has been offering useful products at low prices ... connected to multiple GB connections to ensure that there ...
(Date:9/16/2014)... 16, 2014 Recently, the top experts ... lot of SEO hosting suppliers and announced that GoDaddy ... suppliers for webmasters from the USA, UK, Canada, Australia ... VPS and cloud hosting) without spending a large sum ... use shared SEO hosting plans come with as few ...
Breaking Medicine News(10 mins):Health News:Judging a fish by its color: for female bluefin killifish, love is a yellow mate 2Health News:Judging a fish by its color: for female bluefin killifish, love is a yellow mate 3Health News:Home Healthcare Market in Latin America Expected to Reach USD 17.5 Billion in 2020: Transparency Market Research 2Health News:Home Healthcare Market in Latin America Expected to Reach USD 17.5 Billion in 2020: Transparency Market Research 3Health News:Home Healthcare Market in Latin America Expected to Reach USD 17.5 Billion in 2020: Transparency Market Research 4Health News:Home Healthcare Market in Latin America Expected to Reach USD 17.5 Billion in 2020: Transparency Market Research 5Health News:Launched by Luke Sniewski and Claire Robbie, Million Ways to Live is an International Documentary Series on Healthy Living in Different Cultures 2Health News:Launched by Luke Sniewski and Claire Robbie, Million Ways to Live is an International Documentary Series on Healthy Living in Different Cultures 3Health News:Top 10 Best SEO Hosting: These Companies Are The Best Cheap SEO Hosting Suppliers In 2014 2Health News:Great SEO Hosting Suppliers Announced By Top 10 Best SEO Hosting 2
... a virtually eradicated disease that eats through people's skin, ... South America. ,WHO reported that it ... the skin and bone wasting disease Yaws. The disease ... a bacterial infection, can cause debilitating deformations, particularly in ...
... local and international experts, vaulting over a buffer between ... Central province, for the first time. This has created ... Nairobi. ,The buffer was created by the ... Organisation (WHO) and Food and Agricultural Organisation (FAO). ...
... risk of catching bird flu, as the deadly virus is most ... on cats in areas where outbreaks have occurred found that the ... the chilling prospect that the disease could soon easily be spread ... shows that should bird flu ever break out in Britain, cat ...
... predict disease outbreaks may want to tune into more weather ... finding out when an epidemic is imminent because they determine ... ,The techniques can help quicken the response to ... heat wave and global warming is adding urgency to such ...
... of Informatics-led team of researchers has constructed a model ... across the globe// by airliners. ,The study, ... and Containment Intervention," appears in the January issue of ... said to be the world's largest-scale epidemic simulation of ...
... A new study suggests that TEMPE, a topical anesthetic ... treatment for men with premature ejaculation and might be ... study is published in the February issue of the ... UK and Netherlands studied 54 men with premature ejaculation, ...
Cached Medicine News:Health News:Kenya: Alert As Virus Leaps Over Buffer Zone 2Health News:Kenya: Alert As Virus Leaps Over Buffer Zone 3Health News:Cat Owners at Risk of Bird Flu 2Health News:Experts Use Weather to Predict Disease 2Health News:Scientists Assess Risk of Flu Pandemic Spread Via Global Airlines 2Health News:Scientists Assess Risk of Flu Pandemic Spread Via Global Airlines 3Health News:TEMPE Spray Delays Ejaculation 2
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: